A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma

Sheldon A. Weiner, Silvio Aristizabal, David S Alberts, Earl A. Surwit, Kathryn Deatherage-Deuser

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Twenty patients with locally advanced or metastatic cervical carcinoma were treated with mitomycin, vincristine, bleomycin, and cisplatin (MOBP), prior to radiotherapy (RT) of curative intent. Five patients had stage I disease, 2 stage II, 10 stage III, and 3 stage IV. All but one patient with stage I and II disease had nodal metastases. Patients received two courses of MOBP prior to and cisplatin q 3 weeks during RT. Response rates after completion of MOBP and prior to RT were as follows: 3 18 (16.6%) patients had a complete response (CR), 10 18 (55.5%) had a partial response (PR), 3 18 (16.6%) had improvement, and 2 18 (11.1%) had no response (NR). Five patients developed radiation complications. Of 7 patients with stage I and II disease, 6 (86%) currently have no evidence of disease (NED) (median 27 months). Of 13 patients with advanced disease, 3 (23%) are NED (median 17 months), 8 (61.5%) have expired, and 2 (15.4%) are alive with disease. MOBP is associated with significant response rates in the untreated patient but has not improved survival in patients with advanced disease. Patients with early disease and positive nodes may benefit from this regimen.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalGynecologic Oncology
Volume30
Issue number1
DOIs
StatePublished - 1988

Fingerprint

Neoadjuvant Therapy
Bleomycin
Mitomycin
Vincristine
Cisplatin
Carcinoma
Radiotherapy
Radiation
Neoplasm Metastasis

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. / Weiner, Sheldon A.; Aristizabal, Silvio; Alberts, David S; Surwit, Earl A.; Deatherage-Deuser, Kathryn.

In: Gynecologic Oncology, Vol. 30, No. 1, 1988, p. 1-6.

Research output: Contribution to journalArticle

Weiner, Sheldon A. ; Aristizabal, Silvio ; Alberts, David S ; Surwit, Earl A. ; Deatherage-Deuser, Kathryn. / A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. In: Gynecologic Oncology. 1988 ; Vol. 30, No. 1. pp. 1-6.
@article{7fb566486ab34346af59fb3ae1061819,
title = "A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma",
abstract = "Twenty patients with locally advanced or metastatic cervical carcinoma were treated with mitomycin, vincristine, bleomycin, and cisplatin (MOBP), prior to radiotherapy (RT) of curative intent. Five patients had stage I disease, 2 stage II, 10 stage III, and 3 stage IV. All but one patient with stage I and II disease had nodal metastases. Patients received two courses of MOBP prior to and cisplatin q 3 weeks during RT. Response rates after completion of MOBP and prior to RT were as follows: 3 18 (16.6{\%}) patients had a complete response (CR), 10 18 (55.5{\%}) had a partial response (PR), 3 18 (16.6{\%}) had improvement, and 2 18 (11.1{\%}) had no response (NR). Five patients developed radiation complications. Of 7 patients with stage I and II disease, 6 (86{\%}) currently have no evidence of disease (NED) (median 27 months). Of 13 patients with advanced disease, 3 (23{\%}) are NED (median 17 months), 8 (61.5{\%}) have expired, and 2 (15.4{\%}) are alive with disease. MOBP is associated with significant response rates in the untreated patient but has not improved survival in patients with advanced disease. Patients with early disease and positive nodes may benefit from this regimen.",
author = "Weiner, {Sheldon A.} and Silvio Aristizabal and Alberts, {David S} and Surwit, {Earl A.} and Kathryn Deatherage-Deuser",
year = "1988",
doi = "10.1016/0090-8258(88)90038-8",
language = "English (US)",
volume = "30",
pages = "1--6",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma

AU - Weiner, Sheldon A.

AU - Aristizabal, Silvio

AU - Alberts, David S

AU - Surwit, Earl A.

AU - Deatherage-Deuser, Kathryn

PY - 1988

Y1 - 1988

N2 - Twenty patients with locally advanced or metastatic cervical carcinoma were treated with mitomycin, vincristine, bleomycin, and cisplatin (MOBP), prior to radiotherapy (RT) of curative intent. Five patients had stage I disease, 2 stage II, 10 stage III, and 3 stage IV. All but one patient with stage I and II disease had nodal metastases. Patients received two courses of MOBP prior to and cisplatin q 3 weeks during RT. Response rates after completion of MOBP and prior to RT were as follows: 3 18 (16.6%) patients had a complete response (CR), 10 18 (55.5%) had a partial response (PR), 3 18 (16.6%) had improvement, and 2 18 (11.1%) had no response (NR). Five patients developed radiation complications. Of 7 patients with stage I and II disease, 6 (86%) currently have no evidence of disease (NED) (median 27 months). Of 13 patients with advanced disease, 3 (23%) are NED (median 17 months), 8 (61.5%) have expired, and 2 (15.4%) are alive with disease. MOBP is associated with significant response rates in the untreated patient but has not improved survival in patients with advanced disease. Patients with early disease and positive nodes may benefit from this regimen.

AB - Twenty patients with locally advanced or metastatic cervical carcinoma were treated with mitomycin, vincristine, bleomycin, and cisplatin (MOBP), prior to radiotherapy (RT) of curative intent. Five patients had stage I disease, 2 stage II, 10 stage III, and 3 stage IV. All but one patient with stage I and II disease had nodal metastases. Patients received two courses of MOBP prior to and cisplatin q 3 weeks during RT. Response rates after completion of MOBP and prior to RT were as follows: 3 18 (16.6%) patients had a complete response (CR), 10 18 (55.5%) had a partial response (PR), 3 18 (16.6%) had improvement, and 2 18 (11.1%) had no response (NR). Five patients developed radiation complications. Of 7 patients with stage I and II disease, 6 (86%) currently have no evidence of disease (NED) (median 27 months). Of 13 patients with advanced disease, 3 (23%) are NED (median 17 months), 8 (61.5%) have expired, and 2 (15.4%) are alive with disease. MOBP is associated with significant response rates in the untreated patient but has not improved survival in patients with advanced disease. Patients with early disease and positive nodes may benefit from this regimen.

UR - http://www.scopus.com/inward/record.url?scp=0023877727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023877727&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(88)90038-8

DO - 10.1016/0090-8258(88)90038-8

M3 - Article

C2 - 2452769

AN - SCOPUS:0023877727

VL - 30

SP - 1

EP - 6

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -